Community-acquired pneumonia

Lancet

Volumn 362, Issue 9400, 2003, Pages 1991-2001

  File Jr , Thomas M ^a,b,c  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; DOXYCYCLINE FOSFATEX; ERYTHROMYCIN; GATIFLOXACIN; GLYCOPEPTIDE; INFLUENZA VACCINE; KETOLIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ADENOVIRUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BIOAVAILABILITY; CAUSE OF DEATH; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; CIGARETTE SMOKING; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; CORONAVIRUS; COST BENEFIT ANALYSIS; COXIELLA BURNETII; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EMPIRICISM; ENTEROBACTER; FRANCISELLA TULARENSIS; HAEMOPHILUS INFLUENZAE; HISTOPLASMOSIS; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPETENCE; IMMUNOMODULATION; INFLUENZA; INFLUENZA VIRUS; INTENSIVE CARE UNIT; MEDICAL INFORMATION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA PNEUMONIAE; PARAINFLUENZA VIRUS; PENICILLIN RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; VACCINATION;

EID: 0347364864     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)15021-0     Document Type: Conference Paper

References (141)

1. Brown P.D., Lerner S.A. Community-acquired pneumonia. Lancet. 352:1998;1295-1302.
2. Management of community-acquired pneumonia in adults. S Afr Med J. 86:1996;1152-1163.
3. Dorca J., Bello S., Blanquer J., et al. Diagnostico y tratamiento de la neumonia adquirida en la comunidad. Arch Bronconeumol. 33:1997;240-246.
4. Task Force on CAP, Philippine Practice Guidelines Group in Infectious Diseases. Community-acquired pneumonia: clinical practice guideline. PPGG-ID Philippine Society for Microbiology and Infectious Diseases. 1998; 1(2).
5. Heffelfinger J.D., Dowell S.F., Jorgensen J.H., et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 160:2000;1399-1408.
6. Bartlett J.G., Dowell S.F., Mandell L.A., File TM Jr, Musher D.M., Fine M.J. Guidelines from the Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 31:2000;347-382.
7. Mandell L.A., Bartlett J.G., Dowell S.F., File TM Jr, Musher D.M., Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 37:2003;1405-1433.
8. Mandell L.A., Marrie T.J., Grossman R.E., et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the canadian infectious diseases society and the canadian thoracic society. Clin Infect Dis. 31:2000;383-421.
9. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia (American Thoracic Society). Am J Respir Crit Care Med. 163:2001;1730-1754.
10. Vogel F, et al. and Paul Ehrlich Society for Chemotherapy and the German Respiratory Association. Rational treatment of bacterial respiratory tract infections Chemother J 2000; 9: 3-23.
11. Anonymous. Therapeutic Guidelines: antibiotic (version 11). North Melbourne: Therapeutic Guidelines Ltd; 2000.
12. Matsushima T, Kohno S, Saito A, (eds), and the Japanese Respiratory Society Community-Acquired Pneumonia Treatment Guideline Creation Committee. Diagnostic and treatment guideline for community-acquired pneumonia. Tokyo: Japanese Respiratory Society, General Managing Director Ando Massayuki; 2000. [Also reviewed in Yangihar K, Kohno S, Matsushima T. Japanese guidelines for the management of community-acquired pneumonia. Intern J Antimicrob Agents 2001; 18: S45-48.].
13. Grupo de Trabajo de la Asociacion Latinoamericana del Torax (ALAT). Recomendaciones ALAT sobre la neumonia adquirida en la communidad. Arch Bronconeumol 2001; 37: 340-348.
14. What should the initial antibiotherapy for acute community-acquired pneumonia be? How should it be reassessed in case of failure, given the evolution of responsible pathogens and the resistance of pneumococci? Should combined treatment be used? Med Mal Infect. 31:2001;357-363.
15. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56 (suppl 4): iv1-64.
16. Fine M.J., Smith M.A., Carson C.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA. 275:1996;134-141.
17. Nuorti J.C., Farley M.M., Harrison L.H., McGeer A., Kolczak M.S., Breiman R.F. Cigarette smoking and invasive pneumococcal disease. N Eng J Med. 342:2000;681-689.
18. Marston BJ, Plouffe JF, FileTM, Jr, et al, and the CBPIS Study Group. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997; 157: 1709-18.
19. Jokinen C., Heiskanen L., Juvonen H., et al. Microbial aetiology of community-acquired pneumonia in the adult population of four municipalities in eastern Finland. Clin Infect Dis. 15:2001;1141-1154.
20. Dowell S.F., Anderson L.J., Gary HE Jr, et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infec Dis. 174:1996;456-462.
21. Marx A., Gary HE Jr, Marston B.J., et al. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. Clin Infect Dis. 29:1999;134-214.
22. Peiris J.S.M., Lai S.T., Poon L.L.M., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 361:2003;1312-1313.
23. Arancifia F., Bauer T.T., Ewig S., et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa. Arch Intern Med. 162:2002;1849-1858.
24. Park D.R., Sherbin V.L., Goodman M.S., et al. The aetiology of community-acquired pneumonia at an urban public hospital: influence of immunodeficiency virus infection and initial severity of illness. J Infect Dis. 84:2001;268-277.
25. Miyashita N, Fukano H, Niki Y, Matsushima T, Okimoto N. Aetiology of community-acquired pneumonia requiring hospitalization in Japan. Chest 119; 1295-1296.
26. Ruiz-Gonzalez A., Falguera M., Nogues A., et al. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown aetiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med. 106:1999;385-390.
27. Luna C.M., Famiglietti A., Absi R., et al. Community-acquired pneumonia: aetiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest. 118:2000;1344-1354.
28. Scott J.A., Hall A.J., Muyodi C., et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet. 355:2000;1225-1230.
29. Lim W.S., MacFarlane J.T., Boswell T.C.J., et al. Study of community acquired pneumonia aetiology in adults admitted to hospital: implications for management guidelines. Thorax. 56:2001;296-301.
30. Wattanathum A., Chaoprasong C., Nunthapisud P., Chantaratchada S., Limpairojn N., et al. Community-acquired pneumonia in southeast Asia. Chest. 123:2003;1512-1519.
31. File TM Jr, Tan J.S., Plouffe J.F. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am. 12:1998;569-592.
32. Fine M.J., Stone R.A., Singer D.E., et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med. 159:1999;970-980.
33. Vergis E.N., Akbas E., Yu V.L. Legionella as a cause of severe pneumonia. Seminars in Respir Crit Care Med. 21:2000;295-304.
34. Yu V.L., Plouffe J.F., Pastoris M.C., et al. Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis. 186:2002;127-128.
35. Bochud P.Y., Moser F., Erard P., et al. Community-acquired pneumonia. A prospective outpatient study. Medicine. 80:2001;75-87.
36. Falguera M., Sacristan O., Nogues A., et al. Non-severe community-acquired pneumonia: correlation between cause and severity or comorbidity. Arch Int Med. 161:2001;1866-1887.
37. Tan M.J., Tan J.S., File TM Jr. Legionnaire's disease with bacteremic coinfection. Clin Inf Dis. 35:2002;533-539.
38. File TM Jr, Plouffe JF Jr, Breiman R.F., Skelton S.K. Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. Clin Infect Dis. 29:1999;426-428.
39. Metlay J.P., Atlas S.J., Borowsky L.H., Singer D.E. Time course of symptom resolution in patients with community-acquired pneumonia. Resp Med. 92:1998;1137-1142.
40. Kalin M., Ortvist A., Almela M., et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Inf Dis. 182:2000;840-847.
41. Mortensen E.M., Coley C.M., Singer D.E., et al. Arch Intern Med. 162:2002;1059-1064.
42. Metlay J.P., Kapoor W.N., Fine M.J. Does this patient have community-acquired pneumonia? JAMA. 278:1997;1440-1445.
43. Wipf J.E., Lipsky B.A., Hirschmann J.V., et al. Arch Intern Med. 159:1999;1082-1087.
44. Syrjala H., Broas M., Suramo I., Ojala A., Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis. 27:1998;358-363.
45. Aronsky D., Dean N.C. How should we make the admission decision in community-acquired pneumonia? Med Clin N America. 85:2001;1397-1411.
46. Niederman M.S., McCombs J.S., Unger A.N., Kumar A., Popovian R. The cost of treating community-acquired pneumonia. Clin Therapeutics. 20:1998;820-837.
47. Coley C.M., Yi-Hwei L., Medsger A.R., et al. Preference for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med. 156:1996;1565-1571.
48. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 336:1997;243-250.
49. Auble T.E., Yealy D.M., Fine M.J. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. Inf Disease Clin N America. 12:1998;741-759.
50. Atlas S.J., Benzer T.I., Borowsky L.H., et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med. 158:1998;1350-1356.
51. Marras T.K., Gutierrez C., Chan C.K. Applying a prediction rule to identify low-risk patients with community-acquired pneumonia. Chest. 118:2000;1339-1343.
52. Chan S.S., Yuen E.H., Kew J., Cheung W.L., Cocks R.A. Community-acquired pneumonia - implementation of a prediction rule to guide selection of patients for outpatient treatment. Europ J Emerg Med. 8:2001;279-286.
53. Metlay J.P., Fine M.J. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med. 138:2003;109-118.
54. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 58:2003;377-382.
55. Ewing S., Ruiz M., Mensa J., Marcos M.A., Martinez J.A., Arancibia F., Niederman M.S., Torres A. Severe community-acquired pneumonia: assessment of severity criteria. Amer J Resp Crit Care Med. 158:1998;1102-1108.
56. Angus D.C., Marrie T.J., Obrosky D.S., et al. Severe community-acquired pneumonia. Use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med. 166:2002;717-723.
57. Theerthakarai R., El-Halees W., Ismail M., Solis R., Khan M.A. Non-value of the initial microbiological studies in the management of non-severe community-acquired pneumonia. Chest. 119:2001;181-184.
58. Wunderink R.G., Waterer G.W. Appropriate Microbiological Testing in Community-Acquired Pneumonia. Chest. 119:2001;5-7.
59. Ewig S., Schlochtermeier M., Göke N., Niederman M.S. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest. 121:2002;1486-1492.
60. Korsgaard J., Rasmussen T.R., Sommer T., Moller J.K., Jensen J.S., Kilian M. Intensified microbiological investigations in adult patients admitted to hospital with lower respiratory tract infections. Respir Med. 96:2002;344-351.
61. Waterer G.W., Jennings S.G., Wunderink G. The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. Chest. 116:1999;1278-1281.
62. Glerant J.C., Hellmuth D., Schmit J.L., Ducroix J.P., Jounieaux V. Utility of blood cultures in community-acquired pneumonia requiring hospitalization: influence of antibiotic treatment before admission. Resp Medicine. 93:1999;208-212.
63. Campbell S.G., Marrie T.J., Anstey R., Dickinson G., Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia. Chest. 123:2003;1142-1150.
64. Meehan T.P., Fine M.J., Krumholz H.M., et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 278:1997;2080-2084.
65. Roson B., Carratala J., Verdaguer R., et al. Prospective study of the usefulness of sputum gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis. 31:2000;869-874.
66. Stout J.E., Yu V.L. Legionellosis. New Engl J Med. 337:1997;682-687.
67. Waterer G.W., Baselski V.S., Wunderink R.G. Legionella and community-acquired pneumonia: a review of current diagnostic tests from a clinician's viewpoint. Am J Med. 110:2001;41-48.
68. Domínguez J., Galí N., Blanco S., Pedroso P., Prat C., Matas L., Ausina V. Detection of Streptococcus pneumoniae Antigen by a rapid immunochromatographic assay in urine samples. Chest. 119:2001;243-249.
69. Burel E., Dufour P., Gauduchon V., Jarraud S., Etienne J. Evaluation of a rapid immunochromatographic assay for detection of Streptococcus pneumoniae antigen in urine samples. Eur J Clin Microbiol Infect Dis. 20:2001;840-841.
70. Murdoch D.R., Laing R.T., Mills G.D., et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol. 39:2001;3495-3498.
71. Gutierrez F., Rodriequez J.C., Ayelo A., et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis. 36:2003;286-292.
72. Ramirez J.A., Ahkee S., Tolentino A., Miller R.D., Summersgill J.T. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagn Micro and Infect Dis. 24:1996;7-14.
73. Tong C.Y., Donnelly C., Harvey G., Sillis M. Multiplex polymerase chain reaction for the simultaneous detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Chlamydia psittaci in respiratory samples. J Clin Path. 52:1999;257-263.
74. Menendez R., Cordoba J., de La Cuadra P., Cremades M.J., Lopez-Hotagas J.L., Salavert M., Gobernado M. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med. 159:1999;1868-1873.
75. Scott J.A.G., Hall A.J. The value and complications of percutaneous transthoracic lung aspiration for the etiologic diagnosis of community-acquired pneumonia. Chest. 116:1999;1716-1732.
76. Ishida T., Hashimoto T., Arita M., Osawa M., Tachibana H., Nishioka M., Ito I. Efficacy of transthoracic needle aspiration in community-acquired pneumonia. Intern Med. 40:2001;849-850.
77. Doern G.V., Heilmann K.P., Huynh H.K., et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison or resistance rates since 1994-1995. Antimicrob Agents and Chemo. 45:2001;1721-1729.
78. Whitney C.G., Farley M.M., Hadler J., et al. Increasing Prevalence of Multidrug-Resistant Streptococcus pneumoniae in the United States. N Engl J Med. 343:2000;1917-1924.
79. Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvallez M., Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, -1999. Clin Infect Dis ; 32. 2001:(suppl 2):1997;S81-93.
80. Felmingham D. Evolving Resistance Patterns in Community-acquired Respiratory Tract Pathogens: First Results from the PROTEKT Global Surveillance Study. J Infection. 44:(suppl A):2002;3-10.
81. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN and the Alexander project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired lower respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-46.
82. Richter S.S., Heilmann K.P., Coffman S.L., et al. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Diseases. 34:2002;330-339.
83. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis. 2:2002;404-415.
84. Watanabe H., Sato S., Kawakami K., et al. A comparative clinical study of pneumonia by penicillin-resistant and sensitive Streptococcus pneumoniae in a community hospital. Respirology. 5:2000;59-64.
85. Moroney J.F., Fiore A.E., Harrison L.H., et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis. 33:2001;797-805.
86. Klugman K.P., Feldman C. Streptococcus pneumoniae respiratory tract infections. Curr Opin in Inf Dis. 14:2001;173-179.
87. Metlay J.P. Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes. Curr Opin in Inf Dis. 15:2002;163-167.
88. File TM Jr. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of B-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis. 34:(suppl):2002;S17-S26.
89. Musher D.M., Bartlett J.G., Doern G.V. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to ( lactam antibiotics. Arch Intern Med. 161:2001;2538-2544.
90. File TM, Jr, Jacobs MR, Michael D, Poole MD, Wynne B, and the 546, 547, 548, 549, 550, 551, 556, 557 and 592 Clinical Study Groups. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxicillin/clavulanate. Int J Antimicrob Agents 2002; 20: 235-247.
91. Feikin D.R., Schuchat A., Kolczak M., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 90:2000;223-229.
92. Metlay J.P., Hofmann J., Cetron M.S., et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 30:2000;520-528.
93. Campbell GDJr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis. 26:1998;1188-1195.
94. Leclercq R., Courvalin P. Resistance to macrolides and related 95 antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother. 46:2002;2727-2734.
95. Amsden G.W. Pneumococcal macrolide resistance - myth or reality? J Antimicrob Chemother. 44:1999;1-6.
96. Bishai W. The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother. 49:2002;433-436.
97. Lynch JP, III, Martinez F.J. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis. 34:(suppl 1):2002;S27-46.
98. Siegel R.E. The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia. Are we looking in the wrong place? Chest. 116:1999;535-538.
99. Rodvold K.A., Gotfried M.H., Danziger L.H., et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother. 41:(6):1997;1399-1402.
100. Hyde T.B., Gay K., Stephens D.S., et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 286:2001;1857-1862.
101. Fogarty C., Goldschmidt R., Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis. 31:2000;613-615.
102. Kelley M.A., Weber D.J., Gilligan P., et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis. 31:2000;1008-1011.
103. Musher D.M., Dowell M.E., Shortridge V.D., et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med. 346:2002;630-631.
104. Lonks J.R., Garau J., Gomez L., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae Clin Infect Dis. 35:2002;556-559.
105. Nishijima T., Saito Y., Aoki A., et al. Distribution of mefE and ermB genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibility to various antibiotics. J Antimicrob Chemother. 43:1999;637-643.
106. Chen D, McGeer A., de Azavedo JC, Low DE and Canadian Bacterial Surveillance Network (1999). Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-39.
107. Ho P.L., Yung R.W.H., Tsang D.N.C., et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother. 48:2001;659-665.
108. McGee L., Goldsmith C.E., Klugman K.P. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones J Antimicrob Chemother. 49:2002;173-176.
109. Davidson R., Cavalcanti R., Brunton J.L., et al. Levofloxacin treatment failures of pneumococcal pneumonia in association with resistance. New EnglJ Med. 346:2002;L747-750.
110. Kays N.B., Smith D.W. Levofloxacin treatment failure in a patient with fluoroquinolone resistant Streptococcus pneumoniae pneumonia Pharmacother. 22:2002;395-399.
111. Ho P.L., Tse W.S., Tsang K.W., et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis. 32:2001;701-707.
112. Leclercq R. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. J Antimicrob Chemother. 48:(suppl B):2001;9-23.
113. Stahl J.E., Barza M., DesJardin J., et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med. 159:1999;2576-2580.
114. Gleason P.P., Meehan T.P., Fine J.M., et al. Association between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 159:1999;2562-2572.
115. Dudas V., Hopefl A., Jacobs R., et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother. 34:2000;446-452.
116. Houck P.M., MacLehose R.F., Niederman M.S., et al. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest. 119:2001;1420-1426.
117. Waterer G.W., Somes G.W., Wunderink R.G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 161:2001;1837-1842.
118. Martinez J.A., Horcajada J.P., Almeda M., et al. Addition of a macrolide to a (β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 36:2003;389-395.
119. File TM Jr, Mandell L.A. What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? Clin Infect Dis. 36:2003;396-398.
120. Hedlund J., Ortqvist A., Ahlquist T., Augustinsson A., Beckman H., et al. Management of patients with community-acquired pneumonia treated in hospital in Sweden. Scand J Infect Dis. 34:2002;887-892.
121. Kirk O., Glenthoj J., Dragsted U.B., et al. Penicillin as empirical therapy for patients hospitalized with community acquired pneumonia at a Danish hospital. Danish Medical Bulletin. 48:2001;84-88.
122. Metersky M.L. Community-acquired pneumonia: process of care studies. Curr Opin Inf Dis. 15:2002;169-174.
123. Rhew D.C., Tu G.S., Ofman J., et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med. 161:2001;722-727.
124. Ramirez J.A., Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med. 161:2001;848-850.
125. Rhew D.C., Hackner D., Henderson L., et al. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest. 113:1998;142-146.
126. Halm E.A., Fine M.J., Kapoor W.N., Singer D.E., Marrie T.J., Siu Al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 162:2002;1278-1284.
127. Rhew D.C. Quality indicators for the management of pneumonia in vulnerable elders. Annals Int Med. 135:2001;736-743.
128. Bratzler D.W., Houck P.M., Nsa W., et al. Initial processes of care and outcomes in elderly patients with pneumonia. Ann Emerg Med. 38:(suppl):2001;S36.
129. Dedier J., Singer D.E., Chang Y., Moore M., Atlas S. Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med. 161:2001;2099-2104.
130. Benenson R., Magalske A., Cavanaugh S., Williams E. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Academic Emerg Med. 6:1999;1243-1248.
131. Marrie T.J., Lau C.Y., Wheeler, Wong C.J., Vandervoort M.K., Feagan B.G. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA. 283:2000;749-755.
132. Dean N.C., Silver M.P., Bateman K.A., James B., Hadlock C.J., Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med. 110:2001;541-547.
133. Battleman D.S., Callahan M., Thaler H.T. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia. Arch Intern Med. 162:2002;682-688.
134. Dobbin C.J., Duggan C.J., Barnes D.J. The efficacy of an antibiotic protocol for community-acquired pneumonia. Med J Aust. 174:2001;333-337.
135. Menendez R., Ferrando D., Valles J.M., et al. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest. 122:2002;612-617.
136. Nathwani D., Rubinstein E., Barlow G., Davey P. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis. 32:2001;728-741.
137. Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Practice Physicians. MMWR Morb Mortal Week Rep 2002; 51: No RR-2.
138. Gardner P., Pickering L.K., Orenstein W.A., Gershon A.A., Nichol K. Guidelines for quality standards for immunization. Clin Infect Dis. 35:2002;503-511.
139. Cornu C., Yzebe D., Leophonte P., Gaillt J., Boissel J.P., Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine. 19:2001;4780-4790.
140. Klugman K.P. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. The Lancet Inf Dis. 1:2001;85-91.
141. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New Engl J Med. 348:2003;1737-1746.